Bipolar androgen therapy (BAT) given before sipuleucel‑T appears to increase the rate and magnitude of PA2024‑specific immune responses in men with metastatic castration‑resistant prostate cancer (mCRPC), compared with historical sipuleucel‑T data. The central interpretation is not that BAT by itself generates this immune response, but that BAT may prime the tumor and immune environment so […]
A new, promising concept was explored for men with metastatic castration‑resistant prostate cancer: PSMA‑targeted CAR‑NK cells engineered to be an off‑the‑shelf immunotherapy that aims to combine targeted tumor killing with a safer toxicity profile. The work, presented at AUA 2026 meeting, comes from investigators affiliated with the Cancer Hospital, Chinese Academy of Medical Sciences, who […]
Antibody–drug conjugates (ADCs) have transformed therapy in several malignancies, but in advanced prostate cancer they have mostly been evaluated for direct tumor cytotoxicity, with little attention to immune mechanisms that might underpin durable responses. A recent study introduces a new STEAP1‑targeted ADC platform built on vandortuzumab, an antibody directed at six‑transmembrane epithelial antigen of the […]
A new clinical trial has recently begun for a promising but complex type of cancer treatment called BPX-601, designed specifically for men dealing with advanced prostate cancer that has stopped responding to traditional therapies. This therapy is a form of CAR T-cell treatment, which means doctors take a patient’s own immune cells, reprogram them in […]
PTT‑4256 is an emerging first‑in‑class small‑molecule inhibitor of GPR65, a proton‑sensing G‑protein‑coupled receptor selectively expressed on immune cells within the acidic tumour microenvironment. It is being evaluated in the RAISIC‑1 trial, a modular, open‑label, phase 1/2 study in patients with advanced solid tumours designed to assess safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy. The trial’s […]
AM109 is designed as a bispecific agent that links a PSMA‑targeting humanized antibody to a CD137 (4‑1BB)‑targeting affibody, effectively creating a molecular bridge between prostate cancer cells and T cells in the tumor microenvironment. The rationale is straightforward: by restricting CD137 activation to sites where PSMA is expressed, the therapy aims to drive potent anti‑tumor […]
Castration-resistant prostate cancer (aka androgen pathway modulation resistant prostate cancer, APMR) is one of the toughest forms of prostate cancer to treat. It becomes resistant to hormone therapy, and current immunotherapies don’t work well on it. The main reason is that CRPC tumors create an immune-“cold” environment filled with M2 macrophages, a type of immune […]
A new type of cancer treatment called Bvax is drawing attention in prostate cancer because it may be able to reach inside tumors that are hard to treat with standard immunotherapies. Bvax is made from a patient’s own B cells, which are activated and loaded with tumor‑related proteins, then given back to the body. Once […]
P‑PSMA‑101 is an experimental CAR‑T cell therapy being tested in men with metastatic castration‑resistant prostate cancer (mCRPC) who have already received multiple standard treatments (up to 10 before enrollment). In the phase 1 trial, 33 men with heavily pretreated mCRPC received P‑PSMA‑101, an autologous PSMA‑targeted CAR‑T product enriched in stem‑cell‑like memory T cells and engineered […]
EBNK-001 represents a promising advancement in cancer immunotherapy as an “off-the-shelf” allogeneic natural killer (NK) cell product designed for multi-dose administration in patients with advanced solid tumors. Unlike autologous therapies that require individual patient cell harvesting and processing, EBNK-001 leverages healthy donor-derived NK cells, enabling immediate availability without lengthy manufacturing delays. This off-the-shelf approach addresses […]
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
Accept settingsHide notification onlySettingsWe may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.
If you do not want that we track your visit to our site you can disable tracking in your browser here:
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds:
The following cookies are also needed - You can choose if you want to allow them:
You can read about our cookies and privacy settings in detail on our Privacy Policy Page.
Privacy Policy